Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.2%

20 terminated/withdrawn out of 132 trials

Success Rate

84.3%

-2.3% vs industry average

Late-Stage Pipeline

11%

15 trials in Phase 3/4

Results Transparency

32%

34 of 107 completed trials have results

Key Signals

3 recruiting34 with results18 terminated

Enrollment Performance

Analytics

Phase 1

75(57.7%)

Phase 2

38(29.2%)

Phase 3

13(10.0%)

N/A

2(1.5%)

Phase 4

2(1.5%)

130Total

Phase 1(75)

Phase 2(38)

Phase 3(13)

N/A(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (132)

Showing 20 of 132 trials

NCT05856448Phase 2Completed

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Role: lead

NCT05695950Phase 2Completed

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Role: lead

NCT04985435Phase 4Recruiting

Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)

Role: collaborator

NCT07000890Not ApplicableCompleted

Rheumatoid Arthritis Synovial Tissue Biopsy Study

Role: collaborator

NCT05697159Recruiting

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Role: collaborator

NCT03201445Phase 2Terminated

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Role: lead

NCT05479058Phase 3Terminated

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Role: lead

NCT04720183Phase 1Completed

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Role: lead

NCT04097938Phase 1Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Role: lead

NCT04971746Phase 1Completed

Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Role: lead

NCT04856358Phase 1Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Role: lead

NCT05272683Phase 1Completed

Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects

Role: lead

NCT04106297Phase 1Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

Role: lead

NCT04578548Phase 2Terminated

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Role: lead

NCT02914600Phase 3Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Role: lead

NCT02065700Phase 2Completed

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

Role: lead

NCT03926195Phase 2Completed

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Role: lead

NCT01130818Phase 1Completed

First-in-Human Single Ascending Dose of GLPG0492

Role: lead

NCT02914561Phase 3Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Role: lead

NCT06043739Phase 1Completed

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Role: lead